EUCTR2008-000803-26-DE进行中（未招募）不适用
A controlled randomized double-blind multi-center phase II study of FOLFOX6 or FOLFIRI combined with sorafenib versus placebo in second-line metastatic colorectal carcinoma - FOLFOX6/FOLFIRI plus Sorafenib in second-line Colorectal cancer (FOSCO)
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Age > 18 years
- •2. ECOG Performance Status of 0 to 2
- •3. Life expectancy of at least 12 weeks
- •4. Subjects with at least one uni-dimensional (RECIST) measurable lesion of
- •metastatic colorectal carcinoma after first-line chemotherapy with an
- •Oxaliplatin- or Irinotecan based Fluoropyrimidine containing regimen ±
- •bevacizumab and had a progression subsequently. Lesions must be
- •measured by CT-scan or MRI.
- •5. Adequate bone marrow, liver and renal function as assessed by the following
- •laboratory requirements to be conducted within 7 days prior to screening
- •· Hemoglobin > 9.0 g/dl
- •· Absolute neutrophil count (ANC) >1,500/mm3
- •· Platelet count ³ 100,000/µl
- •· Total bilirubin < 1.5 times the upper limit of normal
- •· ALT and AST < 2.5 x upper limit of normal (< 5 x upper limit of normal for
- •patients with liver involvement of their cancer)
- •· Alkaline phosphatase < 4 x upper limit of normal
- •· PT-INR/PTT < 1.5 x upper limit of normal [Patients who are being
- •therapeutically anticoagulated with an agent such as coumadin or heparin
- •will be allowed to participate provided that no prior evidence of underlying
- •abnormality in these parameters exists.]
- •· Serum creatinine < 1.5 x upper limit of normal
- •6. Signed and dated informed consent before the start of specific protocol
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. History of cardiac disease: congestive heart failure >NYHA class 2; active CAD (MI more than 6 mo prior to study entry is allowed); cardiac arrythmias requiring anti-arrythmic therapy (beta blockers or digoxin are permitted) or uncontrolled hypertension
- •2. History of HIV infection or chronic hepatitis B or C
- •3. Active clinically serious infections (> grade 2 NCI-CTC version 3.0)
- •4. Symptomatic metastatic brain or meningeal tumors (unless the patient is > 6 months from definitive therapy, has a negative imaging study within 4 weeks of study entry and is clinically stable with respect to the tumor at the time of study entry)
- •5. Patients with seizure disorder requiring medication (such as steroids or anti-epileptics)
- •6. History of organ allograft
- •7. Patients with evidence or history of bleeding diathesis
- •8. Patients undergoing renal dialysis
- •9. Known deficit in Dihydropyrimidine Deshydrogenase (DPD)
- •10. Contraindications for the use of atropine in patients receiving FOLFIRI
- •11. Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors [Ta, Tis & T1] or any cancer curatively treated > 3 years prior to study entry.
- •12. Peripheral sensory neuropathy > CTC grade 2
- •13. Chronic inflammatory bowel disease; ileus; genetic fructose intolerance
- •14. Pregnant or breast-feeding patients.
- •15. Women of childbearing potential must have a negative pregnancy test performed within 7 days before the start of treatment. Fertile women and men (<2 years after last menstruation in women) must use effective means of contraception (intrauterine contraceptive device, contraceptive implants, injectables (hormonal depot), transdermal hormonal contraception (contraceptive patch), sexual abstinence or vasectomised partner) during treatment and for at least 6 months after last administration of medication.
- •16. Substance abuse, medical, psychological or social conditions that may interfere with the patient?s participation in the study or evaluation of the study results
- •17. Any condition that is unstable or could jeopardize the safety of the patient and their compliance in the study
- •18. Patients unable to swallow oral medications.
- •Excluded therapies and medications, previous and concomitant:
- •1. 1.Any other anticancer chemotherapy or immunotherapy during the study or within 4 weeks of study entry
- •2. Radiotherapy during study or within 3 weeks of start of study drug. (Palliative radiotherapy will be allowed). Major surgery within 4 weeks of start of study
- •3. Autologous bone marrow transplant or stem cell rescue within 4 months prior to study treatment
- •4. Use of biologic response modifiers, such as G-CSF, within 3 week of study entry. [G-CSF and other hematopoietic growth factors may be used in the management of acute toxicity such as febrile neutropenia when clinically indicated or at the discretion of the investigator, however, they may not be substituted for a required dose reduction.] [Patients taking chronic erythropoietin are permitted provided no dose adjustment is undertaken within 2 months prior to the study or during the study]
- •5. Investigational drug therapy outside of this trial during or within 4 weeks of study entry
- •6. Prior exposure to the study drug.
- •7. Any St. John´s wort containing remedy
研究者
相似试验
进行中（未招募）
1 期
A clinical trial to evaluate the effect of the anti-viral drug Valganciclovir in brain tumor patientsGlioblastoma is an incurable brain tumor with very dismal prognosis. Substantial evidence demonstrates that cytomegalovirus (CMV) is present in 90-100% of malignant glioblastoma.We have observed that valganciclovir is well tolerated among glioblastoma patients receiving temozolomide and radiation therapy. We further observed that treatment with valganciclovir may enhance the survival chances for glioblastoma patients. We aim to assess the efficacy of Valganciclovir in glioblastoma patients.EUCTR2019-001083-30-SEKarolinska Institutet220
已完成
不适用
A double-blind multi-centre randomised controlled trial to investigate the effectiveness of methylprednisolone injections in the treatment of Morton's neuromaMorton's neuromaNervous System DiseasesMononeuropathies of lower limbISRCTN13668166Queen Margaret University (UK)150
已完成
4 期
An intervention study to determine if a longer duration of antibiotics (compared to shorter duration) improves the short and long term clinical outcomes of children hospitalised for pneumoniaPneumonia in childrenRespiratory - Other respiratory disorders / diseasesInfection - Studies of infection and infectious agentsPublic Health - Other public healthACTRN12616000046404Menzies School of Health Research324
招募中
3 期
Preventing recurrent acute lower respiratory infections in young Indigenous children using long-term, once-weekly azithromycin: a multicentre randomised controlled trialAcute lower respiratory infection in childrenRespiratory - Other respiratory disorders / diseasesInfection - Other infectious diseasesACTRN12619000456156Menzies School of Health Research160
尚未招募
1 期
A multicenter randomized double-blind controlled study on the staged prevention and treatment of early retinal degeneration in high myopia by combining disease and syndromeRetinal degeneration of high myopiaITMCTR2200006531Eye Hospital of China Academy of Chinese Medical Sciences